These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 22933513)

  • 21. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension.
    Yoshida S; Shirato K; Shimamura R; Iwase T; Aoyagi N; Nakajima H
    Curr Med Res Opin; 2012 Jun; 28(6):1069-76. PubMed ID: 22506623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.
    Badesch DB; Feldman J; Keogh A; Mathier MA; Oudiz RJ; Shapiro S; Farber HW; McGoon M; Frost A; Allard M; Despain D; Dufton C; Rubin LJ;
    Cardiovasc Ther; 2012 Apr; 30(2):93-9. PubMed ID: 21884013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.
    Li M; Jing ZC; Li Y; Huo Y; Yu Z; Zhang G; Zhu P; Liu J; Ji Q; Wu B; Zhong J; Wang P; Zhu W; Zeng X
    BMC Cardiovasc Disord; 2020 Jul; 20(1):339. PubMed ID: 32680480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.
    Steiner MK; Preston IR
    Vasc Health Risk Manag; 2008; 4(5):943-52. PubMed ID: 19183742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review.
    Peacock AJ; Zamboni W; Vizza CD
    Curr Med Res Opin; 2015; 31(9):1793-807. PubMed ID: 26196225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension.
    Halank M; Knudsen L; Seyfarth HJ; Ewert R; Wiedemann B; Kolditz M; Höffken G; Hoeper MM
    Z Gastroenterol; 2011 Sep; 49(9):1258-62. PubMed ID: 21887662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim Analysis Report).
    Takahashi T; Hayata S; Kobayashi A; Onaka Y; Ebihara T; Hara T
    Clin Drug Investig; 2018 Mar; 38(3):219-229. PubMed ID: 29282676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
    Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
    Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
    Ivy D; Beghetti M; Juaneda-Simian E; Ravindranath R; Lukas MA; Machlitt-Northen S; Scott N; Narita J; Berger RMF
    Eur J Pediatr; 2024 May; 183(5):2141-2153. PubMed ID: 38366267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
    Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
    BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension.
    Klinger JR; Oudiz RJ; Spence R; Despain D; Dufton C
    Am J Cardiol; 2011 Jul; 108(2):302-7. PubMed ID: 21545989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials).
    Maron BA; Waxman AB; Opotowsky AR; Gillies H; Blair C; Aghamohammadzadeh R; Loscalzo J; Leopold JA
    Am J Cardiol; 2013 Sep; 112(5):720-5. PubMed ID: 23751938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ambrisentan therapy for pulmonary arterial hypertension.
    Galié N; Badesch D; Oudiz R; Simonneau G; McGoon MD; Keogh AM; Frost AE; Zwicke D; Naeije R; Shapiro S; Olschewski H; Rubin LJ
    J Am Coll Cardiol; 2005 Aug; 46(3):529-35. PubMed ID: 16053970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.
    Oudiz RJ; Galiè N; Olschewski H; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Harrison BC; Despain D; Dufton C; Rubin LJ;
    J Am Coll Cardiol; 2009 Nov; 54(21):1971-81. PubMed ID: 19909879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.
    Takatsuki S; Rosenzweig EB; Zuckerman W; Brady D; Calderbank M; Ivy DD
    Pediatr Pulmonol; 2013 Jan; 48(1):27-34. PubMed ID: 22511577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
    Zhao Q; Guo N; Chen J; Parks D; Tian Z
    J Clin Pharm Ther; 2022 Feb; 47(2):146-156. PubMed ID: 34319626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension.
    Zhuang Y; Jiang B; Gao H; Zhao W
    Hypertens Res; 2014 Jun; 37(6):507-12. PubMed ID: 24646647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
    Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Vachiery JL; Grünig E; Oudiz RJ; Vonk-Noordegraaf A; White RJ; Blair C; Gillies H; Miller KL; Harris JH; Langley J; Rubin LJ;
    N Engl J Med; 2015 Aug; 373(9):834-44. PubMed ID: 26308684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: A network meta-analysis.
    Duo-Ji MM; Long ZW
    Int J Cardiol; 2017 May; 234():90-98. PubMed ID: 28233631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of ambrisentan in treatment of pulmonary arterial hypertension: a pilot study with 15 patients].
    He J; Wen L; Jiang R; Zhao QH; Wang L; Jiang X; Yan P; Bai L; Jing ZC
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Jun; 41(6):493-6. PubMed ID: 24113042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.